{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gocovri+%28extended-release+amantidine%29",
    "query": {
      "intervention": "Gocovri (extended-release amantidine)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 19,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gocovri+%28extended-release+amantidine%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T14:47:22.408Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02580305",
      "title": "SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "SUVN-502",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Donepezil",
          "type": "DRUG"
        },
        {
          "name": "Memantine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Suven Life Sciences Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 564,
      "start_date": "2015-09",
      "completion_date": "2019-11-07",
      "has_results": true,
      "last_update_posted_date": "2023-06-09",
      "last_synced_at": "2026-09-30T14:47:22.408Z",
      "location_count": 71,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 56 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02580305"
    },
    {
      "nct_id": "NCT01999894",
      "title": "Open-label Study of Safety and Tolerability of Memantine in Children With Autism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism",
        "Pediatric Autism"
      ],
      "interventions": [
        {
          "name": "Memantine HCl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "6 Years to 18 Years"
      },
      "enrollment_count": 102,
      "start_date": "2009-11",
      "completion_date": "2013-02",
      "has_results": true,
      "last_update_posted_date": "2014-03-18",
      "last_synced_at": "2026-09-30T14:47:22.408Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • Sacramento, California • San Francisco, California + 14 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01999894"
    },
    {
      "nct_id": "NCT04387773",
      "title": "Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "GOCOVRI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "50 Years to 80 Years"
      },
      "enrollment_count": 8,
      "start_date": "2020-11-05",
      "completion_date": "2022-09-30",
      "has_results": true,
      "last_update_posted_date": "2024-10-10",
      "last_synced_at": "2026-09-30T14:47:22.408Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04387773"
    },
    {
      "nct_id": "NCT02153645",
      "title": "Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Parkinson's Disease",
        "Levodopa Induced Dyskinesias (LID)"
      ],
      "interventions": [
        {
          "name": "240mg Amantadine HCl ER tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablets",
          "type": "DRUG"
        },
        {
          "name": "320mg Amantadine HCl ER tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Adamas Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "30 Years to 85 Years"
      },
      "enrollment_count": 87,
      "start_date": "2014-08-18",
      "completion_date": "2016-05-20",
      "has_results": true,
      "last_update_posted_date": "2022-02-16",
      "last_synced_at": "2026-09-30T14:47:22.408Z",
      "location_count": 26,
      "location_summary": "Tucson, Arizona • Fountain Valley, California • Irvine, California + 21 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Reseda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02153645"
    },
    {
      "nct_id": "NCT02471222",
      "title": "Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Walking Impairment",
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "ADS-5102",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Adamas Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 60,
      "start_date": "2015-05",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2017-08-08",
      "last_synced_at": "2026-09-30T14:47:22.408Z",
      "location_count": 15,
      "location_summary": "Phoenix, Arizona • Aurora, Colorado • Sarasota, Florida + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Northbrook",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02471222"
    },
    {
      "nct_id": "NCT05045950",
      "title": "Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain Metastases"
      ],
      "interventions": [
        {
          "name": "Memantine -Twice Daily or Extended Release",
          "type": "DRUG"
        },
        {
          "name": "WBRT utilizing the PRDR technique",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2021-11-17",
      "completion_date": "2029-05",
      "has_results": false,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-09-30T14:47:22.408Z",
      "location_count": 2,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05045950"
    },
    {
      "nct_id": "NCT01397422",
      "title": "Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Dyskinesia",
        "Levodopa Induced Dyskinesia",
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "ADS-5102 (extended release amantadine HCl)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Adamas Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "30 Years to 85 Years"
      },
      "enrollment_count": 83,
      "start_date": "2011-07",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2017-12-13",
      "last_synced_at": "2026-09-30T14:47:22.408Z",
      "location_count": 33,
      "location_summary": "Sun City, Arizona • Fountain Valley, California • Long Beach, California + 30 more",
      "locations": [
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01397422"
    },
    {
      "nct_id": "NCT02136914",
      "title": "ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dyskinesia",
        "Levodopa Induced Dyskinesia (LID)",
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "ADS-5102",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Adamas Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "30 Years to 85 Years"
      },
      "enrollment_count": 126,
      "start_date": "2014-05",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2018-02-06",
      "last_synced_at": "2026-09-30T14:47:22.408Z",
      "location_count": 43,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 37 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02136914"
    },
    {
      "nct_id": "NCT07470606",
      "title": "Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain Tumor"
      ],
      "interventions": [
        {
          "name": "Memantine",
          "type": "DRUG"
        },
        {
          "name": "Raloxifene",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 108,
      "start_date": "2026-07-06",
      "completion_date": "2031-07",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-09-30T14:47:22.408Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07470606"
    },
    {
      "nct_id": "NCT07125222",
      "title": "Use of Gocovri to Improve Disability Due to Radiation Encephalopathy",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Encephalopathy",
        "Radiation Effect"
      ],
      "interventions": [
        {
          "name": "Gocovri (extended-release amantidine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2026-09",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-09-30T14:47:22.408Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07125222"
    }
  ]
}